Clinical Trial Update: Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update on the safety and efficacy of the gene therapy vector rAAV2tYF-GRK1-RPGR for X-linked retinitis pigmentosa due to RPGR mutations…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• X-linked Retinitis Pigmentosa

Drugs mentioned

• rAAV2tYF-GRK1-RPGR (RPGR gene therapy vector using AAV2 capsid with tYF-GRK1 modifications)

Snippet

Sponsor: Beacon Therapeutics | Conditions: X-Linked Retinitis Pigmentosa | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING